Premium
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
Author(s) -
Hinder Markus,
Yi B. Alexander,
Langenickel Thomas H.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1010
Subject(s) - heart failure , ejection fraction , clinical trial , medicine , drug development , surrogate endpoint , intensive care medicine , drug , clinical endpoint , drug trial , cardiology , pharmacology
There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.